Pancreatic Cancer Research

ResearcherGerman Cancer Research CenterActive in the last 2 years

Martin Ronald Sprick

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-9691-7574; OpenAlex author ID A5001598846. Sources: OpenAlex.

Their work

Papers
12 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
47
Papers, trials and grants by year

2015: 1 paper · 2016: 2 papers · 2017: 3 papers · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: 1 paper · 2024: none · 2025: 2 papers · 2026: 1 paper

Papers 12

  1. Proteomic Characterization Reveals CYP2S1 as a Mediator of Drug Resistance in PDAC. Co-author DOI 10.1097/mpa.0000000000002553↗
  2. Characterization of single neurons reprogrammed by pancreatic cancer. Co-author DOI 10.1038/s41586-025-08735-3↗
  3. Enhanced mutanome analysis towards the induction of neoepitope-reactive T-cell responses for personalized immunotherapy of pancreatic cancer. Co-author DOI 10.1136/jitc-2025-011802↗
  4. Protocol of the IntenSify-Trial: An open-label phase I trial of the CYP3A inhibitor cobicistat and the cytostatics gemcitabine and nab-paclitaxel in patients w… First author DOI 10.1111/cts.13661↗
  5. Still a hopeless case for personalized oncology? Pancreatic cancer revisited. First author DOI 10.18632/oncoscience.464↗
  6. Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response. Co-author DOI 10.1158/1078-0432.ccr-17-2180↗
  7. High prevalence of incidental and symptomatic venous thromboembolic events in patients with advanced pancreatic cancer under palliative chemotherapy: A retrosp… Co-author DOI 10.1016/j.pan.2017.04.012↗
  8. Survival of pancreatic cancer cells lacking KRAS function. Co-author DOI 10.1038/s41467-017-00942-5↗
  9. Identification and Validation of Novel Subtype-Specific Protein Biomarkers in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000000743↗
  10. CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma. Last author DOI 10.1038/nm.4038↗
  11. Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1080/2162402x.2016.1240859↗
  12. CD95 promotes metastatic spread via Sck in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/cdd.2014.217↗

Closest collaborators

The 25 strongest of 47 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Andreas Trumpp · 11 shared papers, 2015–2026 · strength 1.14
  2. Thilo Hackert · 4 shared papers, 2016–2026 · strength 0.49
  3. Rienk Offringa · 3 shared papers, 2016–2025 · strength 0.43
  4. Albrecht Stenzinger · 4 shared papers, 2016–2025 · strength 0.42
  5. Vera Thiel · 2 shared papers, 2025–2026 · strength 0.41
  6. Elisa M. Noll · 4 shared papers, 2016–2026 · strength 0.40
  7. Wilko Weichert · 5 shared papers, 2015–2019 · strength 0.37
  8. Christoph Roesli · 3 shared papers, 2016–2026 · strength 0.34
  9. Laura Kuhlmann · 2 shared papers, 2017–2026 · strength 0.30
  10. Jens Thomas Siveke · 2 shared papers, 2019–2023 · strength 0.30
  11. Oliver Strobel · 3 shared papers, 2016–2025 · strength 0.30
  12. Nathalia A. Giese · 2 shared papers, 2016–2026 · strength 0.27
  13. Dirk Jäger · 3 shared papers, 2017–2023 · strength 0.27
  14. Christoph Springfeld · 3 shared papers, 2017–2023 · strength 0.27
  15. Michael Volkmar · 2 shared papers, 2016–2025 · strength 0.26
  16. Isabel C. Poschke · 2 shared papers, 2016–2025 · strength 0.26
  17. John P. Neoptolemos · 1 shared paper, 2025 · strength 0.18
  18. Alexander Muckenhuber · 3 shared papers, 2016–2018 · strength 0.17
  19. Karen Steindorf · 1 shared paper, 2023 · strength 0.14
  20. Nicolas Hohmann · 1 shared paper, 2023 · strength 0.14
  21. Azaz Ahmed · 1 shared paper, 2023 · strength 0.14
  22. Jacek Hajda · 1 shared paper, 2023 · strength 0.14
  23. Thomas Theodor Werner Seufferlein · 1 shared paper, 2023 · strength 0.14
  24. Anne Katrin Berger · 2 shared papers, 2017–2018 · strength 0.13
  25. Elisa Espinet Espinet · 2 shared papers, 2016–2017 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.